TELA Bio Misses Q2 Revenue, Withdraws Guidance as New CEO Takes Helm
TELA sits 82% above its 52-week low of $0.501 on elevated volume (3.4× avg).
Summary
TELA Bio reported Q2 revenue of $19.3M, a 4% decline and well below the ~$20.0M expected, driven by lower OviTex PRS volumes and pricing headwinds. New CEO Heather Getz, appointed just days ago, withdrew full-year 2026 guidance, citing the need to reassess the business. She pointed to a return to a cross-selling sales structure and cost-cutting to extend the cash runway. This follows a Q1 that showed accelerating losses and negative equity, and a recent 13D filing by EW Healthcare Partners taking a 17% stake. With $30.4M in cash and ongoing operating losses, the runway is tight. The conference call at 4:30 PM ET may provide more color on the restructuring plan.
At the time of this announcement, TELA was trading at $0.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $41.6M. The 52-week trading range was $0.50 to $2.14. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.